Categories: News

Red Nucleus Launches Medical Communications Business Unit

The new business unit brings together the acquisitions of INVIVO Communications, PPM, OrtleyBio, and most recently MMSG.

YARDLEY, Pa., June 16, 2022 /PRNewswire-PRWeb/ — Red Nucleus (“RN”), a premier provider of strategic learning and development, scientific services and advisory, and medical communications solutions exclusively for the life sciences industry, is pleased to announce that it is consolidating recent acquisitions to form a Medical Communications business unit.

The new business unit brings together the recent acquisitions of INVIVO Communications, PPM, OrtleyBio, and most recently MMSG. This alignment brings new client relationships and touchpoints across commercial and medical affairs and establishes the Medical Communications business unit as a leading digital scientific communications agency with deep therapeutic knowledge and experience integrating innovative technology into communications solutions that engage and delight. Formalizing the Medical Communication business unit is the next step for RN as it works to weave a red thread across the various phases of drug development from molecule to medicine with its clients. Medical Communications has been, and will continue to be, a focus area for RN as it continues its strong growth trajectory.

“We are working tirelessly to provide our clients continuity across the development spectrum with leading products and services. Our Medical Communications business unit, together with our depth of experience in the Scientific Services & Advisory and Learning & Development business units, allows us to offer our clients greater insights and efficiencies across the entire drug life cycle to support them in their journey to improve health outcomes and the quality of people’s lives,” said Red Nucleus CEO Ian Kelly. “We’ve integrated decades of deep scientific knowledge, visual storytelling, and cutting-edge digital solutions into a new, bolder Red Nucleus.”

For more information, please contact
Julie Estrada
jestrada@rednucleus.com
(267) 274-5100

About Red Nucleus
Red Nucleus is a leading provider of scientific and advisory services, digital medical communications, and strategic learning and development, exclusively for the life sciences industry. For 30 years, we’ve taken pride in our long-term relationships with industry leaders, delivering global solutions designed to boost understanding, efficiency, and compliance. With offices in the United States, Japan, the United Kingdom, Sweden, India, Canada, and Australia, our commitment to quality and on-time delivery is unrivaled in the industry.

Visit http://www.rednucleus.com to learn more.

Media Contact

Julie Estrada, Red Nucleus, 1 (267) 274-5100, jestrada@rednucleus.com

 

SOURCE Red Nucleus

Staff

Recent Posts

2026 Payer IT Outsourcing Outlook: Outcome-Based Managed Services, Production-Grade GenAI Governance, and Vendor-Risk Enforcement

Black Book Research Q4 flash survey shows health plans shifting from effort-based sourcing to KPI-backed…

9 hours ago

Cosmos Health Is Building a Platform, and Tariffs Are Accelerating the Strategy

CHICAGO, IL / ACCESS Newswire / December 24, 2025 / Healthcare investors have seen this…

12 hours ago

Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon…

12 hours ago

PharmAla Issues Audited Year End 2025 and Unaudited Q1 Fiscal 2026 Financial Statements

TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”)…

12 hours ago

MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings

Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine CHICAGO, Dec.…

12 hours ago